Current Concepts in Drug Metabolism and Toxicology

Contributors

Membrane Transporters in Drug Development

I Introduction

II Key Features of Transporters

III Transporters and the Pharmaceutical Industry

IV Studying and Contextualizing Transporter Interactions: Application and Interpretation of Data

V The Transporter Toolkit, its Opportunities and Challenges

VI Conclusion

Acknowledgments

Abbreviations

The Keap1–Nrf2 Cell Defense Pathway – A Promising Therapeutic Target?

I Introduction

II The Keap1–Nrf2 Cell Defense Pathway

III Activation of Nrf2 as a Potential Therapeutic Strategy

IV Inhibition of Nrf2 as a Potential Therapeutic Strategy

V Conclusion

Abbreviations

Animal Models of Idiosyncratic Drug Reactions

I Introduction

II Animal Models of Skin Rash

III Animal Models of Liver Toxicity

IV Animal Models of Hematological Toxicity

V Animal Models of Generalized Hypersensitivity Reactions

VI Animal Models of Generalized Autoimmunity

VII Conclusion

Abbreviations

Genetic Polymorphisms Affecting Drug Metabolism

I Introduction

II Recent Advances in the Pharmacogenetics of Cytochromes P450

III Recent Advances in the Pharmacogenetics of Non-P450 Metabolism

IV Clinical Relevance of Polymorphic Metabolism – Some Contemporary Examples

V Conclusion

Abbreviations

Arylamine N-Acetyltransferases – from Drug Metabolism and Pharmacogenetics to Identification of Novel Targets for Pharmacological Intervention

I Introduction

II NAT Enzyme Mechanism

III NAT Genes and Pharmacogenetics

IV The Genomic Distribution and Function of NATs

V NAT Gene Expression and Regulation

VI Development of NAT Inhibitors

VII Conclusion

Abbreviations

Human Pluripotent Stem Cells for Modeling Toxicity

I Introduction

II The Use of Human Stem Cells in Developmental Toxicity

III The Use of Human Stem Cells in Cardiotoxicity

IV The Use of Human Stem Cells in Hepatotoxicity

V The Use of Human Stem Cells in Neurotoxicity

VI Conclusion

Abbreviations

Disposition of Biologics

I Introduction

II Routes of Administration

III Mechanisms of Biologics Distribution and Clearance, The Importance of Active Processes

IV Distribution Studies with Biologics and Relevance to Toxicology Studies

V Metabolism of Biologics

VI Consideration of Immunogenicity – Changes in Disposition and Impact on Toxicology

VII Conclusion

Abbreviations

Index

Recent Volumes in the Serial